B-Type Natriuretic Peptide: Application in the Community

Congestive Heart Failure

Volumn 14, Issue 4, 2008, Pages 12-16

  McDonald, Ken ^a   Dahlström, Ulf ^b   Aspromonte, Nadia ^c   Jourdain, Patrick ^d   Maisel, Alan ^e   Mueller, Christian ^f   Valle, Roberto ^g  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c SPIRITO SANTO HOSPITAL   (Italy)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g Centro per lo Scompenso Ospedale Civile   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIAGNOSTIC AGENT;

HEART FAILURE; HUMAN; MASS SCREENING; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR;

HEART FAILURE; HUMANS; MASS SCREENING; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 55249092048     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2008.08226.x     Document Type: Review

References (30)

1. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation. 1992;86:1081-1088.
2. O'Hanlon R, O'Shea P, Ledwidge M, et al. The biologic variability of B-type natriuretic peptide and N-Terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail. 2007;13:50-55.
3. Wu AH. Serial testing on B-type natriuretic peptide and NT propBNP for monitoring therapy of heart failure; the role of biologic variation in the interpretation of results. Am Heart J. 2006;152:828-834.
4. Bruins S, Fokkema MR, Romer LW, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable heart failure. Clin Chem. 2004;50:2052-2058.
5. Schou M, Gustafsson F, Nielsin PH, et al. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail. 2007;9(1):68-74.
6. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-689.
7. Fonarow GC; ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalises with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21-S30.
8. McCullough PA, Sandberg KR. B-type natri-uretic peptide and renal disease. Heart Fail Rev. 2003;8:355-358.
9. McCullough PA, Duc P, Omland T, et al. B-Type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41:571-579.
10. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides; the endocrine heart revisited. Clin Chem. 2004;50:1503-1510.
11. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure and amino terminal pro-brain natriuretic pep-tide measurement: results from the Pro-BNP Investigation of Dyspnoea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91-97.
12. Mehra MR, Uber PA, Park MH et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol. 2004;43:1590-1595.
13. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-313.
14. Sarzani R, Dessi-Fulgheri P, Paci VM, et al. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest. 1996;19:581-585.
15. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility if a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39:202-209.
16. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure: a population-based study. Eur Heart J. 1999;20:421-428.
17. Aspromonte N, Ceci V, Chiera A, et al. Rapid brain natriuretic peptide test and Doppler echocardiography for early diagnosis of mild heart failure. Clin Chem. c2006;52(9):1802-1808.
18. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of readmission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635-641.
19. Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of B-type natri-uretic peptide (BNP) testing. Eur Heart J. 2003;24(19):1710-1718.
20. Hülsmann M, Berger R, Sturm B, et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J. 2002;23:886-891.
21. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal probrain natriuretic pep-tide and adrenomedullin; prognostic utility and prediction of benefit from carvedilol in chronic ischaemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001;37:1781-1787.
22. Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001;38:1934-1941.
23. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Head J. 2003;24:1735-1743.
24. Gardner RS, Chong KS, Morton JJ, et al. N-terminal brain natriuretic peptide is a more powerful predictor of mortality that endothe-lin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation. Eur J Heart Fail. 2005;7:234-241.
25. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFt). Circulation. 2003;107:1278-1283.
26. Gardner RS, Chong KS, Morton JJ, et al. A change in N-Terminal pro-brain natriuretic peptide is predictive of outcome in patients with advanced heart failure. Eur J Heart Fail. 2007;9:266-271.
27. Lewin J, Ledwidge M, O'Loughlin C, et al. Clinical deterioration in established heart failure: What is the value of BNP and weight gain in aiding diagnosis? Eur J Heart Fail. 2005;7:953-957.
28. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
29. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49:1733-1739.
30. Lainchbury JG, Troughton RW, Frampton CM, et al. NT-proBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail. 2006;8:532-538.